GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Tariff Resilience Score

Infant Bacterial Therapeutics AB (OSTO:IBT B) Tariff Resilience Score : 0/10 (As of Jul. 06, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Tariff Resilience Score?

Infant Bacterial Therapeutics AB has the Tariff Resilience Score of 0, which implies that the company might have .

Infant Bacterial Therapeutics AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Infant Bacterial Therapeutics AB might have .

Infant Bacterial Therapeutics AB  (OSTO:IBT B) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Infant Bacterial Therapeutics AB Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Tariff Resilience Score
Comparable Companies
XSAT:HAMLET B OSTO:FLUO OSTO:MAGLE OSTO:SYNACT OSTO:ACE OSTO:XBRANE OSTO:IMMU OSTO:GUARD XSAT:CESSA OSTO:IVACC VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
9IB:Germany
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines